摘要
目的探究利培酮联合丁螺环酮治疗首发精神分裂症阴性症状患者的疗效及对血清BDNF、S100β、IL-6水平和认知功能的影响。方法随机选取我院2017年4月~2019年12月147精神分裂症患者为研究对象,按照随机化分组法分为联合组(n=73)和对照组(n=74)。对照组给予利培酮治疗,联合组在对照组基础上加以丁螺环酮治疗。比较治疗1个月、2个月后,两组患者疗效、症状改善状况、认知功能和社会功能、脑源性神经营养因子(BDNF)、S100β蛋白(S100β)、白介素-6(IL-6)、肿瘤坏死因子(TNF-α)水平及不良反应情况。结果两组患者疗效比较差异具有统计学意义(P<0.05);两组患者阳性和阴性症状量表(PANSS)评分、MCCB评分、PSP评分的组间、时间点、组间×时间点比较差异具有统计学意义(P<0.05);与治疗前比较,两组患者治疗1个月、2个月后,PANSS各指标评分均依次递减,MCCB及PSP评分均依次递增,组内不同时间点比较差异均有统计学意义(均P<0.05);组间治疗后对比差异均有统计学意义(P<0.05);血清BDNF、S100β、IL-6、TNF-α水平的组间、时间点、组间×时间点比较差异具有统计学意义(P<0.05);与治疗前相比,治疗1个月、2个月后,两组患者血清BDNF水平均依次递增,S100β、IL-6、TNF-α水平均依次递减,组内不同时间点比较差异均有统计学意义(P<0.05);组间治疗后对比差异均具有统计学意义(P<0.05);治疗期间两组患者药物不良反应发生率差异无具有统计学意义(P>0.05)。结论利培酮联合丁螺环酮可有效提高对首发精神分裂症患者阴性症状的疗效,改善患者症状,提高认知能力,降低机体炎症水平,不良反应少。
Objective To explore the efficacy of risperidone combined with buspirone in the treatment of first-episode schizophrenia with negative symptoms and its influence on levels of serum BDNF,S100βand IL-6 and cognitive function.Methods Totally 147 patients with schizophrenia in our hospital were randomly selected as the research subjects.According to the randomized grouping method,the patients were divided into combined group(n=73)and control group(n=74).Control group was treated with risperidone,and combined group was given buspirone on the basis of control group.After 1 month and 2 months of treatment,the efficacy,symptom improvement,cognitive function and social function,levels of serum biochemical indexes[brain-derived neurotrophic factor(BDNF),S100βprotein(S100β),interleukin-6(IL-6),tumor necrosis factor(TNF-α)]and adverse reactions were compared between the two groups.Results The effective rate of clinical treatment was 93.94%in observation group and 78.79%in control group,and there was a significant difference in efficacy between the two groups(P<0.05).The differences in scores of Positive and Negative Symptom Scale(PANSS),MCCB score and PSP score between groups,time points and between groups×time points were statistically significant(P<0.05).Compared with before treatment,the scores of PANSS were significantly reduced in turn while the scores of MCCB and PSP showed a significant increase in sequence after 1 month and 2 months of treatment,and the differences within the group were statistically significant at different time points(P<0.05).The comparisons between groups after treatment were statistically significant(P<0.05).The differences in levels of serum BDNF,IL-6 and TNF-αbetween groups,time points and between groups×time points were statistically significant(P<0.05).Compared with before treatment,the level of serum BDNF of the two groups was risen in sequence while the levels of S100β,IL-6 and TNF-αwere reduced in sequence after 1 month and 2 months of treatment,and there were statistically significant differences at different time points within the group(P<0.05).The comparisons were statistically significant between the groups after treatment(P<0.05).There were no significant differences in the incidence rates of adverse drug reactions between the two groups during treatment(P>0.05).Conclusion Risperidone combined with buspirone for patients with first-episode schizophrenia with negative symptoms can effectively enhance the efficacy,improve the symptoms,increase the cognitive ability and reduce body inflammation level,with few adverse reactions.
作者
蒲新
王应
凡唐
陈光财
王插宇
PU Xin;WANG Ying;FAN Tang;CHEN Guangcai;WANG Chayu(The Fourth Department of Psychiatry,Guangyuan Mental Health Center,Guangyuan 628017,Sichuan,China)
出处
《西部医学》
2022年第4期585-589,共5页
Medical Journal of West China
基金
四川省卫生和计划生育委员会科研课题(16PJ152)。
